Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -14.05% | -62.39% | 60.93% | -27.27% | -25.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.05% | -62.39% | 60.93% | -27.27% | -25.77% |
| Cost of Revenue | -- | -- | -47.75% | -14.97% | -- |
| Gross Profit | -14.05% | -62.39% | 49.46% | 14.75% | -25.77% |
| SG&A Expenses | 14.65% | 52.62% | -0.53% | 24.66% | 3.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.76% | -11.04% | -36.57% | -5.26% | 17.23% |
| Operating Income | 34.93% | 10.65% | 37.74% | 4.98% | -17.79% |
| Income Before Tax | 33.79% | 8.11% | 38.78% | 5.04% | -18.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.79% | 8.11% | 38.78% | 5.04% | -18.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.79% | 8.11% | 38.78% | 5.04% | -18.38% |
| EBIT | 34.93% | 10.65% | 37.74% | 4.98% | -17.79% |
| EBITDA | 35.11% | 10.68% | 37.97% | 4.92% | -18.03% |
| EPS Basic | 35.57% | 10.54% | 50.76% | 33.47% | 20.24% |
| Normalized Basic EPS | 35.57% | 10.54% | 50.77% | 33.46% | 20.22% |
| EPS Diluted | 35.57% | 10.54% | 50.76% | 33.47% | 20.24% |
| Normalized Diluted EPS | 35.57% | 10.54% | 50.77% | 33.46% | 20.22% |
| Average Basic Shares Outstanding | 2.81% | 2.74% | 24.37% | 42.71% | 48.41% |
| Average Diluted Shares Outstanding | 2.81% | 2.74% | 24.37% | 42.71% | 48.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |